全反式维甲酸联合大剂量地塞米松一线治疗新诊断免疫性血小板减少症:多中心开放随机对照2期试验
该多中心开放随机对照2期试验纳入132例新诊断原发免疫性血小板减少症成人患者,比较全反式维甲酸联合大剂量地塞米松与单用大剂量地塞米松的疗效与安全性。
要点
- 联合组6个月持续缓解率68%,单药组41%,差异有统计学意义。
- 常见不良事件为皮肤干燥、头痛、失眠和焦虑/情绪障碍,无4级及以上事件。
- 联合方案可作为新诊断原发免疫性血小板减少症的潜在一线治疗,但需进一步验证。
核心结论
- 全反式维甲酸联合大剂量地塞米松在新诊断原发免疫性血小板减少症患者中安全有效,可提供持续缓解。
- 该联合方案是潜在的一线治疗选择,但需进一步研究验证其疗效和安全性。
研究设计与样本
- 多中心、开放标签、随机对照2期试验,在中国6个三级医疗中心进行。
- 纳入年龄>18岁、未治疗的新诊断原发免疫性血小板减少症成人患者,血小板计数<30×10^9/L或<50×10^9/L伴临床显著出血。
- 按1:1随机分配至全反式维甲酸(10 mg口服,每日两次,共12周)联合大剂量地塞米松(40 mg/日静脉注射,连续4天)组或单用大剂量地塞米松组;若第14天无应答,重复4天地塞米松疗程。
- 主要终点为6个月持续缓解,定义为血小板计数≥30×10^9/L且至少为基线2倍、无出血、无需救援药物。
- 共随机分配132例患者(联合组66例,单药组66例),3例未接受分配治疗,安全性分析集129例。
主要发现
- 联合组最常见不良事件为皮肤干燥(31/64例,48%)、头痛(12/64例,19%)和失眠(12/64例,19%)。
- 单药组最常见不良事件为失眠(10/65例,15%)和焦虑或情绪障碍(8/65例,12%)。
- 两种治疗均耐受良好,未发生4级或更严重不良事件,无治疗相关死亡。
关键数值与推荐
- 6个月持续缓解定义:血小板计数≥30×10^9/L且至少为基线2倍、无出血、无需救援药物。
- 全反式维甲酸剂量10 mg口服每日两次,共12周;地塞米松40 mg/日静脉注射连续4天,若无应答第14天重复4天疗程。
临床怎么用
- 对于新诊断的原发免疫性血小板减少症成人患者,可考虑全反式维甲酸联合大剂量地塞米松作为一线治疗以提供持续缓解。
- 治疗期间需监测皮肤干燥、头痛、失眠及情绪障碍等不良事件。
局限性
- 为2期开放标签试验,样本量有限,需进一步研究验证疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-dose dexamethasone is the standard initial treatment for patients with immune thrombocytopenia, but many patients still relapse and require further treatments. All-trans retinoic acid has been shown to exert immunomodulatory effects and promote thrombopoiesis, and so we aimed to assess the activity and safety of all-trans retinoic acid plus high-dose dexamethasone as a first-line treatment for newly diagnosed patients with immune thrombocytopenia. METHODS: This multicentre, open-label, randomised, controlled, phase 2 trial was done at six different tertiary medical centres in China. Eligible participants were adults (aged >18 years) with treatment-naive, newly diagnosed, primary immune thrombocytopenia who had either a platelet count of less than 30 × 109 platelets per L or a platelet count of less than 50 × 109 platelets per L and clinically significant bleeding. We randomly assigned (1:1) participants to receive either all-trans retinoic acid (10 mg orally twice daily for 12 weeks) plus high-dose dexamethasone (40 mg/day intravenously for 4 consecutive days) or high-dose dexamethasone alone using a central, web-based randomisation system. If patients did not respond by day 14, the 4-day course of dexamethasone was repeated. The primary endpoint was 6-month sustained response, defined as the maintenance of a platelet count of at least 30 × 109 platelets per L and at least 2-times higher than the baseline count and the absence of bleeding, with no need for rescue medication at this time. The primary endpoint was analysed by intention-to-treat and safety was assessed in all participants who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, NCT04217148, and is now completed. FINDINGS: Between Jan 1, 2020, and June 30, 2020, 132 patients were randomly assigned to either all-trans retinoic acid plus high-dose dexamethasone (n=66) or high-dose dexamethasone alone (n=66). Three patients did not receive their allocated treatment, leaving 129 in the safety analysis set. At 6 months, a significantly higher proportion of participants in the all-trans retinoic acid plus high-dose dexamethasone group (45 [68%] of 66) than in the high-dose dexamethasone monotherapy group (27 [41%] of 66) had a sustained response (OR 3·095, 95% CI 1·516-6·318; p=0·0017). The most common adverse events were dry skin (31 [48%] of 64 patients), headaches (12 [19%]), and insomnia (12 [19%]) in the combination group, and insomnia (ten [15%] of 65 patients) and anxiety or mood disorders (eight [12%]) in the monotherapy group. Both treatments were well tolerated and no grade 4 or worse adverse events occurred. There were no treatment-related deaths. INTERPRETATION: The combination of all-trans retinoic acid and high-dose dexamethasone was safe and active in newly diagnosed patients with primary immune thrombocytopenia, providing a sustained response. This regimen represents a potential first-line treatment in this setting, but further studies are needed to validate its efficacy and safety. FUNDING: The Beijing Municipal Science and Technology Commission, the National Natural Science Foundation of China, the Beijing Natural Science Foundation, the National Key Research and Development Program of China, and the Foundation for Innovative Research Groups of the National Natural Science Foundation of China.
引用
- Huang QS, Liu Y, Wang JB, et al. All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Haematol. 2021. PMID: 34560012. doi:10.1016/S2352-3026(21)00240-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。